SCHEMBL6887351

SCHEMBL6887351

O=c1[nH]c(C2CC2)nc2cnc(N3CCN4CCC3CC4)cc12

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.42
PARP1 P09874 2/20 0.40
KCNH2 Q12809 4/20 0.38
PARG Q86W56 1/20 0.37
HTR3A P46098 3/20 0.36
CHRNA7 P36544 1/20 0.36
TMIGD3 P0DMS9 1/20 0.36
ADORA1 P30542 1/20 0.36
TYK2 P29597 1/20 0.35
IP6K1 Q92551 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887762 0.82 TNKS2 (0.42) PARP1KCNH2HTR3ACHRNA7IP6K1
SCHEMBL6887335 0.81 TNKS (0.48) PARP1
SCHEMBL6887831 0.77 KCNH2 (0.39) PARP1KCNH2HTR3ACHRNA7
SCHEMBL6887948 0.76 PARG (0.40) KCNH2PARGHTR3ACHRNA7
SCHEMBL17376087 0.72 ROCK2 (0.51) ROCK2PARP1PARGTMIGD3ADORA1
SCHEMBL6888244 0.71 AADAT (0.35) KCNH2HTR3ACHRNA7
SCHEMBL6888107 0.71 L3MBTL1 (0.37) KCNH2CHRNA7IP6K1
SCHEMBL23293981 0.70 PARP1 (0.51) ROCK2PARP1KCNH2PARGTMIGD3
SCHEMBL6886775 0.70 RAB9A (0.35) KCNH2CHRNA7
SCHEMBL6886990 0.69 KCNH2 (0.44) KCNH2PARGCHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488520-B1 CONDENSED AZINE-DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME (NL) 2015-09-02 EP disclosed
EP-2488520-B1 CONDENSED AZINE-DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME (NL) 2015-09-02 EP disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
WO-2011045258-A1 CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR N.V. ORGANON (NL) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208796-A1 HETEROCYCLIC DERIVATIVES CHRNA5, CHRM5, CHRNA7 ROCK2 2632/4885PARP1 4650/4885KCNH2 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.